Milestones & Highlights

2006 – Present

  • Biosensors presents 9, 12 months and 24 months LEADERS results showing comparable Safety and Efficacy to industry leading drug-eluting stent at ESC and TCT congresses [2008 and 2009]

  • Peer-reviewed article highlighting 9-month LEADERS results published in The Lancet [2008]

  • Biosensors launches BioMatrix™ abluminal biodegradable polymer DES across Europe [2008]

  • Biosensors receives CE Mark approval for its BioMatrix™ abluminal biodegradable polymer DES [2008]

  • Biosensors establishes offices and a direct distributor to support sales presence in China and India for Critical Care products, as well as a new Customer Service department in Switzerland [2006]

  • Biosensors chosen as one of 50 companies to watch by U.S. Medical Device and Diagnostic Industry Publication [2006]

  • Biosensors Japan receives Japanese Ministry of Health, Labor and Welfare approval for its coronary bare metal S-Stent™[2006]

  • Biosensors makes First-In-Man implantation of its BioFreedom™ polymer-free drug-eluting stent [2006]


2000 – 2005

  • Biosensors Singapore manufacturing plants achieved ISO 13485 certification [2005]

  • Biosensors International Group, Ltd is listed on the Mainboard of the Singapore Stock Exchange [2005]

  • Axxion™ drug-eluting stent receives CE Mark approval for commercialization in the European Union countries [2005]

  • Biosensors receives patent from U.S. Patent and Trademark Office covering the use of anti-restenotic, immunosuppressive drugs in combination with a biodegradable drug-release polymer coating on a stent [2005]

  • Biosensors forms Shandong Weigao Biosensors Medical Products Manufacturing Co, Ltd. joint venture in China to manufacture critical care products [2004]

  • Biosensors enters into agreements with specialty stent companies Devax, Inc. and Xtent, Inc. to license Biosensors' biodegradable polymer and Biolimus A9™ anti-restenotic drug. [2004]

  • Biosensors enters into Asset Purchase and Licensing Agreement with Advanced Cardiovascular Systems, Inc., a subsidiary of Guidant Corporation to utilize Biosensors' biodegradable polymer technology and clinical data generated under the FUTURE I and FUTURE II clinical trials conducted by Biosensors [2003]

  • Biosensors enters into agreement with Terumo Corporation with respect to the manufacturing, supply and distribution of Biosensors’ DES technologies on an exclusive basis in Japan and on a non-exclusive basis elsewhere in the world outside of the U.S. [2003]

  • Biosensors acquires Occam International B.V. [2001]


1996 – 2000

  • Biosensors launches Embolectomy catheters [2000]

  • Biosensors launches PTCA catheters [2000]

  • Biosensors develops BIOTRANS™ II and Central Venous Catheter [1999]

  • Biosensors makes its first entry into the interventional cardiology products market with commercialization of its CE Marked S-Stent™ bare metal stent [1999]

  • Biosensors starts development of drug-eluting stents [1999]

  • Biosensors develops its first in-house product, BIOTRANS™ I [1998]

  • Singapore critical care manufacturing plant awarded ISO 9001 quality certification [1996]


1990 – 1995

  • Start of in-house research and development [1995]

  • Biosensors enters into agreement with Sorin Biomedical and Fukuda Denshi as an original equipment manufacturer of critical care products [1992-1995]

  • Food and Drug Administration audits Singapore critical care products manufacturing plant [1992]

  • Biosensors appointed as original equipment manufacturer of critical care products for Argon Medical Devices, Inc. [1991]

  • Biosensors commences global distribution of critical care products [1991]

  • Manufacturing facilities for critical care products are set up in Singapore [1991]

  • Biosensors International Pte Ltd is founded by Yoh-Chie Lu as a contract manufacturing company for critical care products [1990]